However, differential expression of FAM19A5 in lean humans and individuals suffering from obesity has not been reported yet, and FAM19A5 could be regarded either a biomarker or a potential drug target of obesity-related cardiovascular disease in humans (Zarzour et al., 2018). This evidence concerns the gene TAFA5 and obesity disorder.